Who are Letermovir for secondary prophylaxis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Letermovir IV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/letermovir-for-secondary-prophylaxis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Letermovir for secondary prophylaxis — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Letermovir for secondary prophylaxis (Letermovir for secondary prophylaxis) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CMV terminase inhibitor. Area: Infectious Disease / Virology.

marketed CMV terminase inhibitor CMV terminase (UL56 protein complex) Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Letermovir for secondary prophylaxis (Letermovir for secondary prophylaxis) — Institute of Hematology & Blood Diseases Hospital, China. Letermovir inhibits the cytomegalovirus (CMV) terminase complex, preventing viral DNA packaging and replication.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Letermovir for secondary prophylaxis TARGET	Letermovir for secondary prophylaxis	Institute of Hematology & Blood Diseases Hospital, China	marketed	CMV terminase inhibitor	CMV terminase (UL56 protein complex)
Letermovir IV	Letermovir IV	Merck Sharp & Dohme LLC	phase 3	CMV terminase inhibitor	CMV UL56 terminase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CMV terminase inhibitor class)

Institute of Hematology & Blood Diseases Hospital, China · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Letermovir for secondary prophylaxis — Competitive Intelligence Brief. https://druglandscape.com/ci/letermovir-for-secondary-prophylaxis. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab